Search results
Showing 8356 to 8370 of 8912 results
Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)
This evidence summary has been updated and replaced by NICE guideline NG71.
This advice has been updated and replaced by NICE guideline NG199.
This evidence summary has been updated and replaced by NICE advice ESNM26.
This evidence summary has been withdrawn because the product is no longer available in the UK.
Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)
This evidence summary has been withdrawn because the product is no longer available in the UK.
This evidence summary has been withdrawn as the licence of ingenol mebutate gel has been suspended.
This evidence summary has been replaced by ESNM48
Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)
This evidence summary has been updated and replaced by NICE guideline CG61.
Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)
This evidence summary has been updated and replaced by NICE guideline NG217.
Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)
This evidence summary has been updated and replaced by NICE guideline CG97.
This evidence summary has been updated and replaced by NICE guideline NG87.
This guidance has been updated and replaced by NICE HealthTech guidance 623.
This guidance has been updated and replaced by NICE HealthTech guidance 622.
Lutonix drug-coated balloon for peripheral arterial disease (MIB72)
NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.
This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.